Medicus Pharma (NASDAQ:MDCX) Announces Quarterly Earnings Results

Medicus Pharma (NASDAQ:MDCX) issued its quarterly earnings data on Thursday. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.13), Zacks reports.

Medicus Pharma Stock Up 5.3%

Shares of NASDAQ:MDCX traded up $0.02 during midday trading on Thursday, hitting $0.34. The stock had a trading volume of 1,573,236 shares, compared to its average volume of 4,490,042. The company’s 50-day moving average price is $0.45 and its 200-day moving average price is $1.25. The company has a market capitalization of $14.09 million, a P/E ratio of -0.12 and a beta of -0.47. Medicus Pharma has a fifty-two week low of $0.25 and a fifty-two week high of $8.94.

Hedge Funds Weigh In On Medicus Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in shares of Medicus Pharma in the 2nd quarter valued at approximately $41,000. HRT Financial LP bought a new stake in shares of Medicus Pharma during the 4th quarter valued at approximately $42,000. Osaic Holdings Inc. grew its holdings in shares of Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after purchasing an additional 9,000 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after purchasing an additional 17,611 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Medicus Pharma during the 3rd quarter valued at approximately $59,000.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on MDCX shares. Roth Mkm began coverage on shares of Medicus Pharma in a research note on Tuesday, April 21st. They issued a “buy” rating for the company. D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Medicus Pharma in a research report on Monday, April 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Medicus Pharma in a research report on Friday, April 10th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Medicus Pharma presently has a consensus rating of “Hold” and an average price target of $9.00.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.